SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir

• Published in: International journal of biological macromolecules 2023-01, Vol.226, p.946-955
• Main Authors: Wang, Maofeng, Wu, Cancan, Liu, Nan, Zhang, Fengyu, Dong, Hongjie, Wang, Shuai, Chen, Min, Jiang, Xiaoqiong, Zhang, Kundi, Gu, Lichuan
• Format: Article
• Language: English
• Subjects: Antiviral Agents - chemistry; COVID-19; Diphosphates; Eye Proteins; Humans; Molnupiravir; Nerve Tissue Proteins; Nucleoside diphosphate; Nucleosides; Nucleotides; RNA; RNA dependent RNA polymerase; RNA, Viral - genetics; RNA-Dependent RNA Polymerase - metabolism; SARS-CoV-2; SARS-CoV-2 - metabolism
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2022.12.112

The coronavirus disease 2019 has been ravaging throughout the world for three years and has severely impaired both human health and the economy. The causative agent, severe acute respiratory syndrome coronavirus 2 employs the viral RNA dependent RNA polymerase (RdRp) complex for genome replication and transcription, making RdRp an appealing target for antiviral drug development. Systematic characterization of RdRp will undoubtedly aid in the development of antiviral drugs targeting RdRp. Here, our research reveals that RdRp can recognize and utilize nucleoside diphosphates as a substrate to synthesize RNA with an efficiency of about two thirds of using nucleoside triphosphates as a substrate. Nucleoside diphosphates incorporation is also template-specific and has high fidelity. Moreover, RdRp can incorporate β-d-N4-hydroxycytidine into RNA while using diphosphate form molnupiravir as a substrate. This incorporation results in genome mutation and virus death. It is also observed that diphosphate form molnupiravir is a better substrate for RdRp than the triphosphate form molnupiravir, presenting a new strategy for drug design.